BIOYF:OTC-BioSyent Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 6.49

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BioSyent Inc (BIOYF) Stock Analysis:
Based on the BioSyent Inc stock forecasts from 0 analysts, the average analyst target price for BioSyent Inc is not available over the next 12 months. BioSyent Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioSyent Inc is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, BioSyent Inc’s stock price was USD 6.49. BioSyent Inc’s stock price has changed by -6.75% over the past week, -17.22% over the past month and +4.01% over the last year.

No recent analyst target price found for BioSyent Inc
No recent average analyst rating found for BioSyent Inc

About

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supp ...Read More

Company Website : https://www.biosyent.com

Address : 2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.94

52 Week High : 7.93

52 Week Low : 5.50

200 Day Moving Average : 6.37

50 Day Moving Average : 7.07

Shares Held By Insiders : 39.42%

Shares Held by Institutions : 1.28%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.45 (+1.36%)

 USD72.20B 22.76 13.89
MKGAF MERCK Kommanditgesellschaft au..

+4.00 (+2.41%)

 USD72.00B 22.44 13.89
TKPHF Takeda Pharmaceutical Company ..

+0.31 (+1.10%)

 USD44.09B 13.07 0.06
SGIOF Shionogi & Co. Ltd

+0.05 (+0.09%)

 USD16.01B 21.15 0.11
SGIOY Shionogi & Co. Ltd

+0.01 (+0.11%)

 USD16.01B 21.17 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

-0.15 (-3.33%)

 USD15.75B 17.30 2.67
ESALF Eisai Co. Ltd

N/A

 USD12.67B 27.89 0.10
ESALY Eisai Co. Ltd

-0.44 (-1.01%)

 USD12.09B 27.39 0.10
GNHAF Vifor Pharma AG

N/A

 USD11.36B 77.87 17.10
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

 USD10.43B 79.00 0.21

ETFs Containing BIOYF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.07% 75% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.07% 73% C 66% D
Trailing 12 Months  
Capital Gain 4.33% 90% A- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.33% 87% B+ 73% C
Trailing 5 Years  
Capital Gain 13.46% 70% C- 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.46% 70% C- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 3.45% 41% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.45% 40% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 40.32% 79% C+ 56% F
Risk Adjusted Return 8.56% 46% F 32% F
Market Capitalization 0.08B 78% C+ 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.31 36% F 38% F
Price/Book Ratio 3.28 29% F 29% F
Price / Cash Flow Ratio 17.23 7% F 10% F
EV/EBITDA 6.58 43% F 39% F
Management Effectiveness  
Return on Equity 21.53% 94% A 86% B
Return on Invested Capital 21.08% 81% B- 82% B-
Return on Assets 14.46% 99% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.94 50% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.